Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297852 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL450612 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL14232499 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL24017129 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL8934995 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL24017118 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL11454917 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL444477 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL16432729 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA | |
| SCHEMBL3974471 | 0.97 | OPRM1 (0.60) | OPRM1CYP2D6SPHK1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490724-A | Organic phosphine compound based on cyclophane skeleton and its use | 浙江大学 | 2022-12-20 | — | — | CN | claimed |
| JP-10002862-A | — | — | None | — | — | JP | disclosed |
| CN-116607132-A | Plating bath composition for electroless gold plating and method of depositing gold layer | 埃托特克德国有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-115490724-A | Organic phosphine compound based on cyclophane skeleton and its use | 浙江大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-109071580-B | Material for organic electroluminescent device | 默克专利有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3779446-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | University of Massachusetts (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | UNIVERSITY OF MASSACHUSETTS | 2021-01-28 | — | — | US | disclosed |
| CN-111018911-B | Chiral 1, 2-di (hetero) aryl ethylenediamine compound and preparation method thereof | 西南大学 | 2020-12-08 | — | — | CN | disclosed |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3084445-B1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | UNIV MASSACHUSETTS (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20030157170-A1 | Micellar drug delivery vehicles and precursors thereto and uses thereof | ANGIOTECH INTERNATIONAL GMBH (CH) | 2003-08-21 | — | — | US | disclosed |
| US-20030144570-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-07-31 | — | — | US | disclosed |
| WO-2003059408-A2 | SURGICAL PATCHES WITH A BIOLOGICAL ACTIVE AGENT | ANGIOTECH INTERNATIONAL AG (CH) | 2003-07-24 | — | — | WO | disclosed |
| JP-2002338531-A | METHOD FOR PRODUCING TRANS-1,2-DIARYLETHANEDIAMINE AND ITS DERIVATIVE AND TRANS-1,2-DIARYLETHANEDIAMINE DERIVATIVE | SATOU FUMIE | 2002-11-27 | — | — | JP | disclosed |
| EP-1235598-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | Angiotech Pharmaceuticals, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-20020055666-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2002-05-09 | — | — | US | disclosed |
| WO-2001036007-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| JP-H102862-A | IMMOBILIZING REAGENT FOR DETECTING FLUORESCENCE OF CATECHOL COMPOUND AND VANILLYL COMPOUND, AND DETECTING METHOD THEREFOR | BUNSHI BIO PHOTONICS KENKYUSHO:KK | 1998-01-06 | — | — | JP | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
| US-4379159-A | Antiinflammatory 2-substituted-thio-4,5-dihydro-4,5-diaryl-1H-imidazoles | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1983-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | TP53, CIP2A, ABCC1 | OPRM1 4222/4885CYP2D6 3764/4885SPHK1 3909/4885 |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | TP53, CIP2A, ABCC1 | OPRM1 4222/4885CYP2D6 3764/4885SPHK1 3909/4885 |
| US-20030157170-A1 | Micellar drug delivery vehicles and precursors thereto and uses thereof | SLCO1B1, SLCO2A1, BMX | OPRM1 112/4885CYP2D6 304/4885SPHK1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.